• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者经过 15 年随访,原发于甲状腺髓样癌及其淋巴结转移的基因改变。

Genetic alterations in a primary medullary thyroid carcinoma and its lymph node metastasis in a patient with 15 years follow-up.

机构信息

Departamento de Medicina y Nutrición, División de Ciencias de la Salud, Campus León, Universidad de Guanajuato, Guanajuato, Mexico.

出版信息

Diagn Pathol. 2012 Jun 7;7:63. doi: 10.1186/1746-1596-7-63.

DOI:10.1186/1746-1596-7-63
PMID:22676344
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3443442/
Abstract

BACKGROUND

Association between DNA alterations and clinical parameters as recurrence, survival or prognosis has been found in a variety of tumors. A clear association between Medullary Thyroid Carcinoma (MTC) and RET oncogene mutation has been accepted. Specifically M918T RET mutation represents the main genetic event in most cases of sporadic MTC (SMTC) and limited chromosomal alterations analyses have been performed.

METHODS

In the present work, a comparative genomic hybridization (CGH) study was performed using DNA from a primary tumor in a M918T RET mutation-positive SMTC patient and from its lymph node metastasis to investigate additional genetic alterations. We studied a patient with 15 years of follow-up and persistence of disease, confirmed by periodical elevated serum calcitonin (CT) levels.

RESULTS

Only 3 chromosomal imbalances were identified in the primary tumor, gain of 18p, and loss of 6p and 16p region, whereas 25 chromosomal imbalances were identified in the metastasis (9 gains and 16 losses).

CONCLUSION

The chromosomal changes 6p-, 16p-, 18p + could determine in part the oncogenic phenotype in the primary M918T RET positive tumor and probably related to persistence of high serum CT levels in this patient. The additional chromosomal changes observed could be related to the metastasis phenotype. We suggest that some genes mapped at 6p, 16p and 18p chromosomal regions, could act as genes associated to cancer and could be related to persistent SMTC and good prognosis.

VIRTUAL SLIDES

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1720753793691097.

摘要

背景

在各种肿瘤中,已经发现 DNA 改变与复发、生存或预后等临床参数之间存在关联。髓样甲状腺癌 (MTC) 与 RET 癌基因突变之间的明确关联已被接受。具体而言,M918T RET 突变代表了大多数散发性 MTC (SMTC) 的主要遗传事件,并且已经进行了有限的染色体改变分析。

方法

在本工作中,对 M918T RET 突变阳性 SMTC 患者的原发肿瘤及其淋巴结转移中的 DNA 进行了比较基因组杂交 (CGH) 研究,以研究其他遗传改变。我们研究了一位 15 年随访且疾病持续存在的患者,通过定期升高的血清降钙素 (CT) 水平得到证实。

结果

在原发肿瘤中仅发现 3 个染色体不平衡,即 18p 的增益和 6p 和 16p 区域的丢失,而在转移瘤中发现了 25 个染色体不平衡(9 个增益和 16 个丢失)。

结论

6p-、16p-、18p+染色体变化部分决定了 M918T RET 阳性原发肿瘤的致癌表型,并且可能与该患者血清 CT 水平持续升高有关。观察到的额外染色体变化可能与转移表型有关。我们建议,映射到 6p、16p 和 18p 染色体区域的一些基因可能作为与癌症相关的基因起作用,并且可能与持续存在的 SMTC 和良好的预后有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8da7/3443442/57f7e76d8720/1746-1596-7-63-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8da7/3443442/57f7e76d8720/1746-1596-7-63-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8da7/3443442/57f7e76d8720/1746-1596-7-63-1.jpg

相似文献

1
Genetic alterations in a primary medullary thyroid carcinoma and its lymph node metastasis in a patient with 15 years follow-up.患者经过 15 年随访,原发于甲状腺髓样癌及其淋巴结转移的基因改变。
Diagn Pathol. 2012 Jun 7;7:63. doi: 10.1186/1746-1596-7-63.
2
CGH alterations in medullary thyroid carcinomas in relation to the RET M918T mutation and clinical outcome.甲状腺髓样癌中与RET M918T突变及临床结局相关的比较基因组杂交改变
Int J Oncol. 2001 Jun;18(6):1219-25. doi: 10.3892/ijo.18.6.1219.
3
RET Proto-oncogene Gene Mutation Is Related to Cervical Lymph Node Metastasis in Medullary Thyroid Carcinoma.RET 原癌基因的基因突变与甲状腺髓样癌的颈部淋巴结转移相关。
Endocr Pathol. 2019 Dec;30(4):297-304. doi: 10.1007/s12022-019-09588-z.
4
Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.CDKN2C基因拷贝数在散发性甲状腺髓样癌中的作用
Thyroid. 2016 Nov;26(11):1553-1562. doi: 10.1089/thy.2016.0224. Epub 2016 Oct 18.
5
High-resolution analysis of alterations in medullary thyroid carcinoma genomes.高分辨率分析甲状腺髓样癌基因组的改变。
Int J Cancer. 2012 Jul 15;131(2):E66-73. doi: 10.1002/ijc.26494. Epub 2011 Nov 28.
6
Medullary thyroid carcinoma: long-term outcomes of surgical treatment.甲状腺髓样癌:手术治疗的长期结果。
Ann Surg Oncol. 2011 Jan;18(1):219-25. doi: 10.1245/s10434-010-1339-y. Epub 2010 Sep 28.
7
Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.循环RET M918T突变肿瘤DNA在晚期甲状腺髓样癌患者中的预后意义
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3591-3599. doi: 10.1210/jc.2017-01039.
8
A cohort study on 10-year survival of sporadic medullary thyroid carcinoma with somatic RET mutation.一项关于伴有体细胞RET突变的散发性甲状腺髓样癌10年生存率的队列研究。
Kaohsiung J Med Sci. 2016 Nov;32(11):545-551. doi: 10.1016/j.kjms.2016.08.012. Epub 2016 Oct 14.
9
S409Y Germline Mutation and Associated Medullary Thyroid Carcinoma.S409Y 种系突变与相关的甲状腺髓样癌。
Thyroid. 2019 Oct;29(10):1447-1456. doi: 10.1089/thy.2018.0385. Epub 2019 Sep 11.
10
Genome-wide copy number analysis in a family with p.G533C RET mutation and medullary thyroid carcinoma identified regions potentially associated with a higher predisposition to lymph node metastasis.对一个携带p.G533C RET突变且患有甲状腺髓样癌的家族进行全基因组拷贝数分析,确定了可能与更高淋巴结转移易感性相关的区域。
J Clin Endocrinol Metab. 2014 Jun;99(6):E1104-12. doi: 10.1210/jc.2013-2993. Epub 2014 Mar 6.

引用本文的文献

1
Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas.应用移码终止分析检测甲状腺乳头状癌 BRAF V600 突变。
Diagn Pathol. 2013 Jul 24;8:121. doi: 10.1186/1746-1596-8-121.
2
Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis.CK-19、半乳糖凝集素-3 和 HBME-1 在甲状腺病变分化中的表达:系统评价和诊断荟萃分析。
Diagn Pathol. 2012 Aug 13;7:97. doi: 10.1186/1746-1596-7-97.

本文引用的文献

1
A census of amplified and overexpressed human cancer genes.人类癌症基因扩增和过表达的普查。
Nat Rev Cancer. 2010 Jan;10(1):59-64. doi: 10.1038/nrc2771.
2
Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways.侵袭性遗传性和散发性髓样甲状腺癌显示出相似的致癌途径。
Endocr Relat Cancer. 2009 Dec;16(4):1261-72. doi: 10.1677/ERC-08-0289. Epub 2009 Aug 12.
3
Alternative surgical strategies and favorable outcomes in patients with medullary thyroid carcinoma in Japan: experience of a single institution.
日本甲状腺髓样癌患者的替代手术策略及良好预后:单机构经验
World J Surg. 2009 Jan;33(1):58-66. doi: 10.1007/s00268-008-9795-2.
4
High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma.高分辨率阵列比较基因组杂交分析揭示了与甲状腺髓样癌相关的脱氧核糖核酸拷贝数改变。
J Clin Endocrinol Metab. 2008 Nov;93(11):4367-72. doi: 10.1210/jc.2008-0912. Epub 2008 Sep 2.
5
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.散发性甲状腺髓样癌中体细胞RET癌基因突变的预后意义:一项10年随访研究
J Clin Endocrinol Metab. 2008 Mar;93(3):682-7. doi: 10.1210/jc.2007-1714. Epub 2007 Dec 11.
6
Comparative genomic hybridization.比较基因组杂交
Annu Rev Genomics Hum Genet. 2005;6:331-54. doi: 10.1146/annurev.genom.6.080604.162140.
7
Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma.在家族性和散发性甲状腺髓样癌中鉴定出的全基因组拷贝数失衡。
J Clin Endocrinol Metab. 2003 Apr;88(4):1866-72. doi: 10.1210/jc.2002-021155.
8
RET oncogene mutations in medullary thyroid carcinoma in Mexican families.墨西哥家族性甲状腺髓样癌中的RET原癌基因突变
Arch Med Res. 2003 Jan-Feb;34(1):41-9. doi: 10.1016/s0188-4409(02)00461-7.
9
CGH alterations in medullary thyroid carcinomas in relation to the RET M918T mutation and clinical outcome.甲状腺髓样癌中与RET M918T突变及临床结局相关的比较基因组杂交改变
Int J Oncol. 2001 Jun;18(6):1219-25. doi: 10.3892/ijo.18.6.1219.
10
Prognostic value of codon 918 (ATG-->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma.密码子918(ATG→ACG)RET原癌基因突变在散发性甲状腺髓样癌中的预后价值。
Int J Cancer. 2001 Jan 20;95(1):62-6. doi: 10.1002/1097-0215(20010120)95:1<62::aid-ijc1011>3.0.co;2-1.